801 related articles for article (PubMed ID: 18628464)
1. Phase II trial of curcumin in patients with advanced pancreatic cancer.
Dhillon N; Aggarwal BB; Newman RA; Wolff RA; Kunnumakkara AB; Abbruzzese JL; Ng CS; Badmaev V; Kurzrock R
Clin Cancer Res; 2008 Jul; 14(14):4491-9. PubMed ID: 18628464
[TBL] [Abstract][Full Text] [Related]
2. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis.
Li L; Braiteh FS; Kurzrock R
Cancer; 2005 Sep; 104(6):1322-31. PubMed ID: 16092118
[TBL] [Abstract][Full Text] [Related]
3. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products.
Kunnumakkara AB; Diagaradjane P; Guha S; Deorukhkar A; Shentu S; Aggarwal BB; Krishnan S
Clin Cancer Res; 2008 Apr; 14(7):2128-36. PubMed ID: 18381954
[TBL] [Abstract][Full Text] [Related]
4. Curcumin down regulates smokeless tobacco-induced NF-kappaB activation and COX-2 expression in human oral premalignant and cancer cells.
Sharma C; Kaur J; Shishodia S; Aggarwal BB; Ralhan R
Toxicology; 2006 Nov; 228(1):1-15. PubMed ID: 16996673
[TBL] [Abstract][Full Text] [Related]
5. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model.
Mach CM; Mathew L; Mosley SA; Kurzrock R; Smith JA
Anticancer Res; 2009 Jun; 29(6):1895-9. PubMed ID: 19528445
[TBL] [Abstract][Full Text] [Related]
6. The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia.
Song XQ; Lv LX; Li WQ; Hao YH; Zhao JP
Biol Psychiatry; 2009 Mar; 65(6):481-8. PubMed ID: 19058794
[TBL] [Abstract][Full Text] [Related]
7. Suppression of interleukin 6 and 8 production in head and neck cancer cells with curcumin via inhibition of Ikappa beta kinase.
Cohen AN; Veena MS; Srivatsan ES; Wang MB
Arch Otolaryngol Head Neck Surg; 2009 Feb; 135(2):190-7. PubMed ID: 19221248
[TBL] [Abstract][Full Text] [Related]
8. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis.
Li L; Aggarwal BB; Shishodia S; Abbruzzese J; Kurzrock R
Cancer; 2004 Nov; 101(10):2351-62. PubMed ID: 15476283
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer.
Sharma RA; McLelland HR; Hill KA; Ireson CR; Euden SA; Manson MM; Pirmohamed M; Marnett LJ; Gescher AJ; Steward WP
Clin Cancer Res; 2001 Jul; 7(7):1894-900. PubMed ID: 11448902
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance.
Sharma RA; Euden SA; Platton SL; Cooke DN; Shafayat A; Hewitt HR; Marczylo TH; Morgan B; Hemingway D; Plummer SM; Pirmohamed M; Gescher AJ; Steward WP
Clin Cancer Res; 2004 Oct; 10(20):6847-54. PubMed ID: 15501961
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of imatinib mesylate in patients with metastatic pancreatic cancer.
Gharibo M; Patrick-Miller L; Zheng L; Guensch L; Juvidian P; Poplin E
Pancreas; 2008 May; 36(4):341-5. PubMed ID: 18437079
[TBL] [Abstract][Full Text] [Related]
12. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model.
Kang HJ; Lee SH; Price JE; Kim LS
Breast J; 2009; 15(3):223-9. PubMed ID: 19645775
[TBL] [Abstract][Full Text] [Related]
13. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients.
Kanai M; Otsuka Y; Otsuka K; Sato M; Nishimura T; Mori Y; Kawaguchi M; Hatano E; Kodama Y; Matsumoto S; Murakami Y; Imaizumi A; Chiba T; Nishihira J; Shibata H
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1521-30. PubMed ID: 23543271
[TBL] [Abstract][Full Text] [Related]
14. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway.
Wang D; Veena MS; Stevenson K; Tang C; Ho B; Suh JD; Duarte VM; Faull KF; Mehta K; Srivatsan ES; Wang MB
Clin Cancer Res; 2008 Oct; 14(19):6228-36. PubMed ID: 18829502
[TBL] [Abstract][Full Text] [Related]
15. Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy.
Logan RM; Gibson RJ; Sonis ST; Keefe DM
Oral Oncol; 2007 Apr; 43(4):395-401. PubMed ID: 16979925
[TBL] [Abstract][Full Text] [Related]
16. Contribution of degradation products to the anticancer activity of curcumin.
Shen L; Ji HF
Clin Cancer Res; 2009 Nov; 15(22):7108; author reply 7108-9. PubMed ID: 19903776
[No Abstract] [Full Text] [Related]
17. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma.
Feng W; Brown RE; Trung CD; Li W; Wang L; Khoury T; Alrawi S; Yao J; Xia K; Tan D
Ann Clin Lab Sci; 2008; 38(3):195-209. PubMed ID: 18715846
[TBL] [Abstract][Full Text] [Related]
18. Effect of curcumin on nuclear factor kappaB signaling pathways in human chronic myelogenous K562 leukemia cells.
Reuter S; Charlet J; Juncker T; Teiten MH; Dicato M; Diederich M
Ann N Y Acad Sci; 2009 Aug; 1171():436-47. PubMed ID: 19723087
[TBL] [Abstract][Full Text] [Related]
19. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials.
Shehzad A; Wahid F; Lee YS
Arch Pharm (Weinheim); 2010 Sep; 343(9):489-99. PubMed ID: 20726007
[TBL] [Abstract][Full Text] [Related]
20. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences.
Garcea G; Berry DP; Jones DJ; Singh R; Dennison AR; Farmer PB; Sharma RA; Steward WP; Gescher AJ
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):120-5. PubMed ID: 15668484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
